Join to View Full Profile
200 1st Street SWRochester, MN 55905
Dr. Yoon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board-certified medical oncologist with a clinical specialization in GI cancers and cancers of unknown primary (CUP) My research focuses on clinical trials of novel agents and translational investigations in gastroesophageal and colorectal cancer and in CUP.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2008
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
Yale School of MedicineClass of 2001
Johns Hopkins University Schools of Medicine and Public HealthMHS, Clinical Investigation
Certifications & Licensure
MN State Medical License 2008 - 2025
MD State Medical License 2004 - 2009
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery Start of enrollment: 2007 May 11
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jun 24
- Join now to see all
Publications & Presentations
PubMed
- Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.Muhammad Umair Anjum, Syed Arsalan Ahmed Naqvi, Salman Ayub Jajja, Ammad Raina, Muhammad Umar Afzal
The Oncologist. 2025-08-04 - Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases.Samuel D Butensky, Varun V Bansal, David G Su, Muhammad Talha Waheed, Andrei Nikiforchin
Cancer. 2025-07-01 - Consensus Guideline for the Management of Gastric Cancer with Synchronous Peritoneal Metastases.Samuel D Butensky, Varun V Bansal, David G Su, Muhammad Talha Waheed, Andrei Nikiforchin
Annals of Surgical Oncology. 2025-06-25
Lectures
- Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- From Standardization to Personalized Care: How to Use Molecular Diagnostics to Guide TreatmentASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (A...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- How Immunotherapy Is Transforming GI Cancer TreatmentHarry Yoon, MD, Op-Med
https://www.doximity.com/articles/01f7f77e-e73f-4d56-9d87-d82c9d8e9faf
UpToDate, Wolters Kluwer Health - 2013-03-12
Authored Content
- How Immunotherapy Is Transforming GI Cancer TreatmentJanuary 2019
Press Mentions
NCCN Clinical Practice Guidelines in Oncology: 2025 UpdatesMay 15th, 2025- Adding PD-1 Inhibitor to Chemoradiation Boosts Complete Response in Resectable Esophageal CancerJanuary 27th, 2025
- Neoadjuvant Chemoradiation plus Immunotherapy Boosts Responses in Esophageal CancerJanuary 24th, 2025
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
